Illustrated glass lab pavilion above a bay, scientists working at the bench

Enterprise Pharma

Imagine your next trial beginning with everything you’ve learned

Altrovia turns your development history, evidence and expertise into agentic workflows every team can use.

Put everything your organization knows to work

Evidence

Make design decisions with evidence

Explore endpoints, populations, treatment windows and design choices across comparable trials, regulatory precedent and your own development history. Every recommendation stays connected to its source, and the choice stays with your team.

Optimization

Find better options before you commit

Agents assess patient burden, site workload and amendment patterns from prior studies while your design takes shape. Compare simpler alternatives that preserve your scientific goals, and surface trade-offs before they become expensive downstream.

Collaboration

Bring every function into the same workflow

Clinical, biostatistics, regulatory and operations teams, and your CRO partners, contribute in parallel, with comments beside each clause and changes routed for review. Capture sign-offs before a version locks, with a clear record of what changed and why.

Case study: Phase 3 oncology

What could preventing three amendments mean for your trial?

Projected impact from Altrovia’s analysis of a Phase 3 oncology trial, assuming three of eight amendments were prevented:

37.5%

Lower operational costs from amendments

More to reinvest in R&D
18 months

Projected time avoided from amendment delays

2 years

Projected earlier time to market

Projections from one Phase 3 oncology analysis, not measured results. Actual costs and timelines depend on the trial’s amendments, execution and study assumptions.

Make your organization’s knowledge reusable

Connect your protocols, amendment histories and recorded decisions. Altrovia combines them with public evidence so agents start every new design from what your organization has already learned. Your data stays within your organization.

Your organization / Data sourcesPrivate to your team
  • ProtocolsConnected
  • Amendment historiesConnected
  • Recorded decisionsConnected

From conversations with clinical teams

“Finding the right evidence is one of the hardest parts of designing the trial, even when it comes from our own previous studies.”
Big pharma, Clinical Trial Leader
“There’s an embarrassing amount of manual work between pharma and CROs, with Excel trackers and systems sitting in their own silos.”
Big pharma, Global Clinical Operations
“We spend months developing a protocol, with multiple internal reviews and executive comments that take too long to resolve.”
Big pharma, Clinical Trial Leader
“We have limited time to review the protocol before submission, yet an amendment can add roughly four months of delay.”
Mid-size pharma, Clinical Operations
“One amendment can block further amendments for at least three months.”
Specialty pharma, Clinical Development Leader